Indication
Squamous NSCLC
3 clinical trials
4 products
1 drug
Product
CPL304110Clinical trial
A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Drug
pembrolizumabProduct
valemetostatClinical trial
Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With PembrolizumabStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Product
PANDA-VACProduct
Pembrolizumab